The Higher Education Funding Council for England (HEFCE) have proposed that higher education institutions (HEIs) eligible to receive public funding for research through HEFCE should comply with a research integrity concordat published earlier this year. A consultation is currently underway inviting comments on whether compliance should become a mandatory requirement for HEIs, and how this might best be monitored.
BU is seeking your views on the two consultation questions:
- Do you agree that compliance with the research integrity concordat should be a condition of HEFCE grant?
- Do you agree with the proposal that demonstrating compliance with the research integrity concordat should be integrated into HEFCE’s existing reporting requirements, and that this represents a proportionate and reasonable way to ensure compliance?
The requirements of the research integrity concordat are summarised in the briefing paper. You can either respond to the consultation individually by noon on Friday 8 March 2013 or submit any views/comments that you would like to be considered for inclusion in BU’s institutional response to Colette Cherry, Policy Advisor to the Vice-Chancellor by noon on Friday 22 February 2013.











BU geography student’s undergraduate dissertation published in international journal
Why some commons survive and others don’t
BU Research blog in 2023 grows into 2026 publication
REF 2029 Sector Survey: Have Your Say
BU methods paper reached 2,500 reads
UKCGE Recognised Research Supervision Programme: Applications Close 19 October
Horizon Europe Cluster 3 (Civil Security for Society) 2026 Calls Now Open
MSCA Doctoral Networks 2026 Call Information Webinar
ESRC Festival of Social Science 2026: Application Deadline Extended to Thursday 25 June 2026
Reminder: Register for the ESRC Festival of Social Science 2026 Information Session
ECR Funding Open Call: Research Culture & Community Grant – Apply now
ERC Advanced Grant 2025 Webinar
Update on UKRO services
European research project exploring use of ‘virtual twins’ to better manage metabolic associated fatty liver disease